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ABSTRACT 
 
 
Hematopoietic stem cell transplantation (HSCT) represents an effective treatment 
strategy for a variety of hematologic and not hematologic malignancies. 
In particular, autologous transplantation of haematopoietic stem cells (ASCT) from 
bone marrow of patients with hematologic malignancies is feasible and has low 
treatment-related mortality (Gribben JG, 2009). However, literature assessed late 
mortality in 29.4% of individuals who had survived 2 or more years after 
autologous haematopoietic cell transplantation (Burns, L.J., 2009; Bhatia S. and 
al, 2005). This could be due to the purified stem cells which might carry a mutation 
on a chromosome predisposing to the disease and lead to the risk of pathology 
recurrence. 
Lymphoma and myeloma are perfect candidates for autologous transplantation 
after G-CSF stimulation and bone marrow ablation trough chemotherapy. 
However, in this case too, pathology relapse or secondary malignancies are found 
in a high percentage of patients. 
The aim of this project is to verify the existence of detectable imbalanced 
chromosome anomalies in stem cells before any ablative treatment for HSCT or 
developed after G-CSF stimulation or chemotherapy. 
A cohort of 24 lymphoma and myeloma patients have been analyzed trough array-
CGH to identify significant imbalanced chromosome anomalies also present in low 
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percentage of mosaicism. The result showed anomalies in 8/24 patients: one 
patient affected by Hodgkin Lymphoma (HL) revealed a deletion of chromosome 2 
in p16.1, where the REL gene is located and in part deleted; the amplification of 
chromosome 11 in q12.2q13.4 containing CCND1 gene (this patient was 
investigated both before and after transplantation) was found in one patient with 
multiple myeloma (MM); alterations of chromosome 14 in q32.31-33, where genes 
for variable chain of immune globulin are located, were found in five patients with 
Hodgkin and non Hodgkin lymphomas (HL/NHL). FISH on interphase nuclei has 
been used to confirm a-CGH data. 
A short-time (36 months) clinical and haematological follow-up examination did not 
show a different trend between patients with chromosome imbalances and without 
but a long-term follow-up is needed to definitely correlate the imbalances with the 
clinical evolution and to have the indications of global survival of the considered 
population. 
Work in progress is the extension of clinical and haematological observation to 
obtain evidence of a difference statistically significant and to reach the final goal of 
suggesting a possible protocol to candidate  patients to purging treatments before 
the CD34+ cells re-infusion. 
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INTRODUCTION 
 
 
Hematopoiesis 
 
Hematopoiesis is the process by which new blood cells are produced each day to 
maintain physiologic functions. The most important players in this process are  
pluripotent hematopoietic stem cells (HSCs) that act as a reservoir that self-renew 
and differentiate on demand to replace senescent and damaged cells during 
embryonic and post-natal life (Marks-Bluth, J and al, 2012).  
During the embryogenesis, HSCs emerge from the aorta-gonad-mesonepheros 
(AGM) and placenta, and expand in the fetal liver where they ensure the 
development of the blood system. These cells are called Fetal HSCs and have 
high proliferative and self-renewal ability. 
Adults develop two subsets of hematopoietic organs, one devoted to the 
production of the myeloid cells and the other to  lymphoid cells. 
Bone marrow is the most important myeloid organ and it is designated to the 
formation of erythrocytes (erythropoiesis), granulocytes (granulocytopoiesis), 
monocytes (monocytopoiesis) and platelets (megakaryocytopoiesis). Thymus and 
bone marrow are the two primary organs in charge of formation of B and T 
lymphocytes (lymphocytopoiesis) whereas secondary organs are spleen and 
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mucosa-associated lymphoid tissue (MALT). The spleen has also hemochateresis 
function during which old erythrocytes and platelets are removed. MALT is a 
diffused lymphoid organ and it includes gut-, bronchial-, nasopharinx-, larynx-, eye, 
vascular- and skin-associated lymphoid tissues. Function of MALT is to ensure a 
complete immune response after local stimulation using both, B and T 
lymphocytes.  
Another function of bone marrow is to supply a specific microenvironment for 
proliferation, differentiation and release of blood cells. Indeed the bone marrow 
contains  cells of haematopoiesis system and also stromal cells with their mature 
elements (fibroblasts, osteoclasts, chondrocytes and adipocytes). These cells 
generate the microenvironment (niche) that let blood cells to grow (Rosati P, et al 
2006). This heterogeneous composition of cells create a structural support, 
synthesizes growth factors and promotes interaction between cells and 
microenviroment. Those interactions are bidirectional: niche regulates stem cell 
self-renewal and cell fate decisions, in turn stem cells modulate the nurturing 
microenvironments in which they reside (Psaila B et al, 2012). 
According to their differentiation potency stem cells can be classified in totipotent,  
pluripotent, multipotent and unipotent (monopotent). During the differentiation, cells 
are subjected to changes in their phenotype and this peculiarity has been 
investigated by the cytofluorometry and FACS. These technologies allowing to 
isolate stem cells have revolutionized stem cell research and clinical practice. 
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Furthermore, they have helped to clarify the hierarchical organization of 
hematopoietic differentiation.  
A great improvement has been generated by the characterization of CD34 antigen. 
Hematopoietic stem cells are contained within the CD34+ compartment and CD34 
antigen is lost during differentiation.  
Most stem cell divisions are asymmetrical, yielding one stem cell keeping the 
quiescent state and a more differentiated cell, which has a limited self-renewal 
ability. Extrinsic instructions provided by unique microenvironments (niches) 
regulate the fate of individual HSCs and progenitors. Specifically, stem cell 
activation is initiated by primary lineage determinants which can ‘transcriptionally 
prime’ multipotential progenitors at a sub-threshold level, establishing a low-level 
expression of a mixed lineage pattern of gene expression. Upon reaching a critical 
threshold of activity, the primary determinants will differentiate the multi-potential 
progenitors along a particular cell-fate through secondary regulators. These 
molecules are transcription factors and cytokines that cooperate or antagonize 
with primary determinants and act ‘locking in’ the decision by repressing the 
alternate lineage and  promoting the uni-lineage choice (Burda P et al, 2010). The 
orientation toward erythroid lineage is mediated by GATA-1, whereas Pu.1 acts 
promoting the lymph-myeloid-one. Further, differentiation derives from added 
cytokines and growth factors activities (Epo, TPO, interleukins, GM- and G-CSF 
each  influencing a single lineage) (Fig 1).  
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Other players in this process are chemokines. Based on their molecular structure, 
these proteins are divided into two major subgroups CCL and CXCL that bind 
CCR and CXCR receptors, respectively. These mediators are important for 
regulation of cell viability, proliferation, differentiation, migration and homing (the 
ability to find destination, or niche).  
 
 
 
 
Recent studies demonstrated that stem cells are gifted of plasticity and that cells 
partially differentiated could be reprogrammed upon particular conditions and 
converted in different hematopoietic lines. For this reason, a lymphoid cell could 
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be converted in a myeloid cell. In pathologic conditions, HSCs may differentiate 
into non-hematological cells according to the need of the body. For example, in 
ischemic brain, transplanted BM cells could differentiate into neurons and 
astrocytes (Woodbury D et al, 2000).  
Furthermore, similar to most organs and tissues, the hematopoietic system shows 
evidence of aging, which is associated with increased incidence of myeloid 
malignancies, myelodysplasia, myeloproliferative neoplasms, chronic anaemia and 
multifactorial immune dysfunction (Rossi DJ, 2008). 
Hematological diseases generally reflect inappropriate regulation or alterations of 
the genetic program controlling complex processes during hematopoiesis.  
These diseases range from disruption of blood cell production leading to absence 
of one or more cellular components (bone marrow failure syndromes) to faulty 
maturation processes such as disordered globin chain switching 
(hemoglobinopathies) to excessive hematopoietic cell production (leukemias). 
Therefore  understanding the mechanisms which regulate the haematopoiesis and 
the immunity system re-establishment  could lead to the decrement of mortality 
caused by hematological diseases and by treatments as allogenic and autogenous 
transplantations. 
 
Blood malignancies 
The hematologic malignancies can be divided into lymphoid and myeloid disorders 
depending on which system is injured. 
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Lymphoid disorders: 
Lymphoid leukaemia is characterized by a diffuse involvement of lymphoid organs 
and also of bone marrow, often associated with a large  number of neoplastic cells 
in the peripheral blood; lymphomas are solid lymphoid proliferations presenting 
often with several lymphoid masses. However, the limit between leukemia and 
lymphoma is not always very well defined and leukaemia may be a lymphoma 
progression. Indeed, neoplastic lymphocytes keep their ability to circulate in the 
blood and the cancer can be spread in lymphatic and  haematic ways. When the 
latter happens may be impossible to distinguish between lymphoma and 
leukaemia. 
Lymphoma is a neoplasm presenting clonal heterogeneity and resulting from 
clonal evolution (Masao Seto, 2013). Genome profile analysis demonstrated that 
genomic alterations may have a hierarchy regarding occurrence. Early and late 
genetic events may exist and some conditions may predispose to lymphoma (as 
acquired immunodeficiency states consecutive to transplantations or AIDS) but  
the pathogenic pathways are not fully understood.   
Lymphomas can be classified in Hodgkin and Non-Hodgkin lymphomas (Fig2). 
Hodgkin's Disease malignant cells usually remain localized in one lymph node or a 
surrounding chain in the neck, shoulder, and chest. Non-Hodgkin lymphoma do 
not contain Reed-Sternberg cells, typical of HL, and tend to develop in peripheral 
lymph nodes and spread throughout the body. 
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  Fig2. Lymphoma classification 
 
Clinic manifestations, diagnosis and staging are similar in both categories. Most 
frequent symptom is the enlargement of lymph-nodes in neck, underarm and groin 
regions. Sometimes fever, asthenia, itch and weight loss could be present; in that 
case lymphoma is indicated as type A, otherwise as type B. The next paragraphs 
describe more in detail the biological aspects of the two kinds of lymphoma.  
                                                                                                                           Introduction          
 8
Hodgkin Disease (Hodgkin Lymphoma, HL): 
It is one of the most frequent lymphomas whose incidence is 3 new cases per 
100000 persons per year in the Western countries. In particular, in 2012, 
approximately 9060 individuals were diagnosed with Hodgkin lymphoma (HL) in 
the United States (US) with about 1190 deaths (American Cancer Society. 
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/
document/acspc-031941.pdf; 2012. [Accessed March 21, 2012] ). Incidence of HL 
increases to 4.5 cases per 100000 in individuals between the ages of 20 and 25, 
decreases slightly through ages 35 and 60, and then increases again to over 4 
cases per 100000 individuals above the age of 70.   
Epstein–Barr virus (EBV) is believed to play a causal role for one third of cases. 
This kind of tumour tends to arise in different members of the same family also of 
far generations. The risk to develop HL increases until 7 times between brothers 
and the probability is even bigger between twins. Anticipation phenomenon is 
observed analyzing tumours of parents and sons: this may have some genetic 
cause. Clinically, HL involves peripheral lymph nodes and, at a later stage, organs 
such as liver, lung, and bone marrow. It is characterized by the proliferation of 
particular mononucleated giant cells (20-60 μm) called Hodgkin cells and 
multinucleated giant cells called Reed-Sternberg (HRS) which constitute a small 
fraction (0.1-5%) of neoplastic tissue, feature that hampers their molecular study 
(Fig.3). Recent analysis of immunoglobulin (Ig) genes revealed that these cells are 
usually clonal B cells since presenting identical rearrangements of Ig heavy and ⁄ 
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or light chain genes. Then somatic hypermutations occur in B lymphocytes of 
germinal centre but HRS cells escape from apoptosis. 
 
Fig.3: Reed-Steinberg cells. Source Licthman MA et al 
Due to reprogramming of gene expression, these HRS cells lose the expression of 
most B-cell specific genes, acquire expression of multiple genes typical of other 
haematopoietic cells and attract various cells of immune system into lymphoma 
tissue resulting in an inflammatory microenvironment. Figure 4 summarizes all 
cellular interactions of HRS cells. 
Indeed, HRS cells show not only constitutive activity of signalling pathways 
normally transiently activated in B cells (such as NF-κB, jak–Stat and PI3K), but 
also activation of signalling molecules and pathways not normally activated in B 
cells (such as NOTCH 1 and multiple receptor tyrosine kinases). 
Furthermore, there is evidence that the recruitment of inflammatory cells into the 
lymphoma microenvironment is essential for HRS cells survival (Küppers, 2009).  
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Fig.4: Cellular interactions in HRS cells microenvironment.                                     
 
Particularly, HRS cells secrete a variety of cytokines and chemokines for T-helper 
2 (Th2) cells including thymus and activation regulated chemokine (TARC) which 
attract CD4+ cells (Van den Berg et al. 1999). Th2 secretes cytokines such as IL-
13 which directly promote HRS survival since these cells express IL-13 receptors 
and signal through the STAT-6 pathway. Subpopulations of CD4+ cells secrete 
interleukin 10 (IL-10), transform growth factor β (TGFβ), inhibit cytotoxic T-cell 
function and protect HRS cells from apoptosis (Marshall et al. 2004). Multiple other 
cytokines secreted by infiltrating cells appear to provide survival signals to the 
HRS cells including CD30, CD40 and NOTCH1, all of which act through TNF 
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family receptors of pro-survival receptors which activate signaling pathways 
including PI3-kinase/Akt/mTOR, ERK/MAPK and NF-κB. The ability to establish an 
inflammatory microenvironment is the essential key to HL pathogenesis.   
From a cytogenetic point of view no chromosome abnormality has been 
demonstrated in HL as isolated change. HRS cells show abnormal karyotypes, in 
fact conventional cytogenetics find chromosome loss or gain in until 92%of 
metaphases.  
In HL, conventional comparative genomic hybridization (CGH) studies have shown 
many chromosome imbalances as recurrent gain of 2p16.1 (including REL 
oncogene which encodes c-Rel, a member of Rel/NFκB transcription factors 
family) and gain of 9p23.24 (including JAK2 which is a member of JAK/STAT 
pathway and promotes cells growth and proliferation). 
Alterations have been found also in 8q24.21 (including PVT1. The PVT1 locus 
encodes several micro-RNAs thought to be important  in T lymphomagenesis and 
T-cell activation. Co-activation of c-Myc and PVT1 has been shown in a variety of 
human tumors as well as prostate, breast, colorectal and prostate cancers). 
ATM (11q22-23) is also mutated in HL (ATM is a tumour suppressor gene that 
regulates the balance between DNA repair and apoptosis in response to DNA 
damage. Mutations of ATM lead to genetically instable diseases as Ataxia 
Telangiectasia). Furthermore two SNPs have been found in 10p149p 
encompassing the transcription factor and putative tumor suppressor gene GATA3 
which encodes the GATA binding protein 3 isoform 2. Expression of GATA3 is 
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important in hematopoietic and lymphoid cell development, acting as a master 
transcription factor for differentiation of Th2 cells. A high proportion of the reactive 
infiltrate in classical Hodgkin lymphoma (cHL) is composed of Th2-like cells with a 
Tregulatory phenotype, which can influence EBV-positive cHL cell growth, depending 
on EBV antigenic presentation by MHC molecules (Enciso-Mora V, 2010). HRS 
show also mutations in IKB and BCL-6 genes (which act as a sequence-specific 
repressor of transcription) 
In spite of the absence of a constant genetic pattern able to explain the disease 
pathogenetic mechanisms, the high frequency of HL among family members and 
the phenomenon of anticipation suggest involvement of genetic factors in its 
etiology. In that sense, human leukocyte antigen (HLA) haplotypes might be 
involved. In fact, Epstein Barr virus (EBV) is a well-established causal factor in a 
subset of HD patients and genetic variation in host anti-viral immune responses 
related to HLA polymorphisms might be an important contributor to the 
development of virally induced malignancies. Study of 934 HL patients shows that 
HLA-A1 was associated with an increased risk for EBV+ HL, whereas HLA-A2 was 
associated with a decreased risk for EBV+ HL (Hjalgrim, 2012). 
 
-Classification- 
HL is divided in two groups which differ substantially in their histopathologic  
pattern and clinical course: classic HL (cHL) and lymphocyte-predominant HL 
(LPHL).  
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cHL is characterized by only a few malignant cells and an abundance of 
inflammatory cells. Hodgkin and Reed–Sternberg (HRS) cells are surrounded by T 
and B cells admixed with plasma cells, macrophages, eosinophils and mast cells. 
These non-malignant cells, recruited and/or induced to proliferate by tumour cells, 
produce soluble or membrane-bound molecules involved in tumour cell growth and 
survival. In particular, no other B-lymphoid malignancy shows such a dramatic loss 
of the B-cell phenotype.  
LPHL  is a rare form of HL (5%) and presents two morphologic patterns, nodular 
and diffuse. In lympho nodes, the nodular pattern is characterized by the presence 
of atypical “lymphocytic and histiocytic” (L&H) or “popcorn” cells, embedded in a 
nonneoplastic nodular background composed mostly of small B lymphocytes. In 
the diffuse pattern, the L&H cells are set against a diffuse background of reactive 
T cells. It shows very good prognosis, especially in early stages without risk 
factors (Nogovà L, 2006). 
 
-Clinical staging and prognosis- 
An accurate evaluation of the malignancy extension is essential for prognosis and 
planning the therapeutic strategy. To this purpose Ann Arbor stage (AAS) is used.  
   
Stage I.         Involvement of a single lymph node region (I) or a single  
                     extra-lymphatic organ or site (IE). 
Stage II.        Involvement of 2 or more lymph node regions on the same  
                     side of the diaphragm (II) or localized involvement of 
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                     extra-lymphatic organ or site and of 1 or more lymph node 
                     regions on the same side of the diaphragm (IIE). An optional 
                     recommendation is that the numbers of node regions involved 
                     be indicated by a subscript [e.g., II3]. 
Stage III.      Involvement of lymph node regions on both sides of the  
                    diaphragm (III), which may also be accompanied by 
                    localized involvement of extra-lymphatic organ or site (IIIE)  
                    or by involvement of the spleen (IIIS), or both (IHSE). 
Stage IV.     Diffuse or disseminated involvement of 1 or more 
                    extra-lymphatic organs or tissues with or without associated 
                    lymph node enlargement. 
 
The elapse of the illness depends also from the number of area involved from the 
disease, the possible bone marrow or liver involvement and from mediastinal 
participation. 
 
-Treatment- 
In most of cases HL is a curable disease trough the first line treatment 
(chemotherapy and/or radiotherapy). However, 15% to 25% of patients relapse or 
do not respond. For these patients, the standard of care is based on autologous 
stem cell transplantation (ASCT). Patients who relapse after ASCT or who are 
refractory to chemotherapy have a very poor prognosis. Allogenic stem cell 
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transplantation (alloSCT) is a treatment option for such patients with controversial 
results (Marcais A, 2013). 
 
-Survival- 
Hodgkin lymphoma has become one of the most easily curable malignancies in 
oncology. However, severe, life-threatening treatment-related side effects occur, 
which include organ toxicity and secondary malignancies. 
In particular, death caused by HL has the strongest impact within 15 years after 
treatment. After 18 years the mortality rate of second cancers (SCs) exceeds the 
one of HL. The high incidence of SCs after HL recovery induced to hypothesize 
the presence of germ-line mutations which can predispose to the development of 
them. Many studies show the correlation between therapy and SCs. Particularly, 
the probability to develop a SC is 10.1% after 15 years and 14.9% after 20 years 
of HL treatment. Radiotherapy seems to be the more important suspected cause 
of solid tumors (especially lung 23%, breast 12% and gastrointestinal 12%); In 
particular, the risk of breast cancer in women treated by irradiation before the age 
of 30 is increased to a level higher than that in 50-year-old women in the general 
population; on the other hand chemotherapy is correlated to secondary 
laeukemias and NHL. Thyroid function disorders are also frequent and may be 
found in up to 80% of patients, depending on study conditions, the form of 
treatment, and the type of test used (Hodgson DC, et al.,2007), (Ng AK, et 
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al.,2008). SCs risk increases with age (5,7% for patients under 28 years, 25,6% 
for patients above 44 years) and with gender (18%vs 8.9%of male vs female). 
 
Non Hodgkin Lymphoma (NHL) 
90% of all lymphomas are referred to as non-Hodgkin lymphoma and more than 
two-thirds of patients are above 60 years of age. Malignant non-Hodgkin 
lymphoma (NHL) has been increasing in incidence worldwide and a study 
involving a North American adult population between 1999 and 2003 
demonstrated a population-based incidence rate of NHL of 1.73 per 100,000, 
higher than in other parts of the western world (JM Howell et al, 2012).  
Non-Hodgkin lymphomas consist in a heterogeneous group of cancers. There are 
now approximately 60 distinct subtypes of NHL listed in the 2008 World Health 
Organization (WHO) classification. 85–90% of the group arise from B lymphocytes; 
the remainder derive from T lymphocytes or NK lymphocytes. This diverse group 
of malignancies usually develops in the lymph nodes, but can occur in almost any 
tissue. Any organ can be the primary site of NHL. However, the gastrointestinal 
tract is the most frequent extranodal site in non-Hodgkin lymphoma, and the 
stomach is the most frequently implicated part of the gastrointestinal tract. 
Immunosuppression is the most well established risk factor for the development of 
NHL. Patients with HIV, organ-transplant recipients, patients who have had high-
dose chemotherapy with stem-cell transplantation, and those with inherited 
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immunodeficiency syndromes or autoimmune disease present an increased risk of 
developing NHL. 
Escape from apoptosis is the way by which lymphomas could develop. Indeed 
during B-cell maturation, cells spring up from the central lymphoid tissues where 
recombination of V, D, and J gene segments results in the assembly of 
immunoglobulin heavy-chain and light-chain genes. 
In this process, two enzymes (RAG1 and RAG2) cause breaks in double-stranded 
DNA. In normal cases, DNA repair processes are activated to resolve them. 
However, these strand breaks can contribute to chromosome translocations which 
typically result in proto-oncogene activation in lymphoma (Shankland KR, 2012). 
For example, the genetic hallmark of follicular lymphoma is the t(14;18) 
chromosome translocation, which juxtaposes BCL2 gene on chromosome 18 to 
the transcription active immunoglobulin heavy-chain region on chromosome 14. 
This translocation can be detected in 80–90% of cases, and up-regulates BCL2, 
which prevents programmed cell death. Anyway, none of these chromosome 
translocation is self sufficient to cause the tumour. It is necessary the 
accumulation of other genetic damages. Unfortunately, the identity of additional 
damages and therefore the mechanism of tumour progression is still unknown.  
 
-Classification- 
The more common types of lymphoma are listed below according to whether they 
are B-cell or T-cell lymphomas. 
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B-cell lymphomas represent most (about 85%) of non-Hodgkin lymphomas in the 
United States and are: 
- Diffuse large B-cell lymphoma (DLBCL): it is a fast growing lymphoma, but it 
often responds well to treatment. 
- Follicular lymphoma: About 1 out of 5 lymphomas. The term follicular means that 
cells tend to grow in a circular pattern in lymph nodes. The average age for people 
with this lymphoma is about 60. Follicular lymphomas are often slow- growing and 
respond well to treatment. 
- Mantle cell lymphoma: Only about 5% of lymphomas are of this type. The cells 
are small to medium in size. It afflicts men most often. The average age of patients 
is in the early 60s.  
- Burkitt lymphoma: This type makes up about 1% to 2% of all lymphomas. Close 
to 90% of patients are male, and the average age in the US is about 30. It is 
named after the doctor who first described this disease in African children and 
young adults. The cells are medium sized. This is a very fast-growing lymphoma 
but more than half of patients can be cured by intensive chemotherapy. 
- Lymphoplasmacytic lymphoma: This type is not common, accounting for 1% to 
2% of lymphomas. The lymphoma cells are small and found mainly in the bone 
marrow, lymph nodes, and spleen.  
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Among T-cell lymphoma there are: 
- Precursor T-lymphoblastic lymphoma/leukemia: This disease accounts for about 
1% of all lymphomas. The cancer cells are small-to-medium sized, immature T-
cells. Patients are most often young adults, with males being affected more often 
than females. This lymphoma is fast-growing, but usually not involving bone 
marrow .When it is first diagnosed the chance of cure with chemotherapy is quite 
good. 
- Peripheral T-cell lymphomas: These types of lymphomas develop from more 
mature forms of T cells. They are rare. 
Table 1 lists the different types of B-cell NHL with their translocations and the 
molecular consequences. 
NHL-B         ANOMALY   (%of cases)    GENE/PROTEIN 
Lymphoplasmacytoid       t(9;14)        (50%)            PAX-5/transc factor 
Follicular           t(14;18)    (70-90%)            BCL-2/Anti-apopt 
Diffuse large B-cell         t(3;many)   (30-40%)            BCL-6/transc factor 
                                        t(11;18)        (30%)            BCL-2/Anti-apopt 
Mantle-cell            t(11;14)      (100%)            BCL-1/ Cyclin D1  
Burkitt   t(8;14), t(8;22), t(2;8)   (100%)            c-MYC/transc factor  
MALT    t(1;14)        (?)  BCL-10/Anti-apopt 
Table1: Distribution of principal chromosome translocations in different NHL-B subtypes, 
frequency, involved proto- oncogenes  and codified proteins. 
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-Clinical staging and prognosis- 
Ann Arbor classification is used in NHL but only 7-10% of patients begin at the I 
stage whereas 70-80% are identified at III-IV stage. 
At the opposite of HL, clinical staging has not prognostic and therapeutic impact.  
The International Prognostic Index (IPI) is the most widely used prognostic model 
for patients with non-Hodgkin lymphoma. Considering as risk factors age ( <60 
years), lactate dehydrogenase concentration, Eastern Cooperative Oncology 
Group performance status, Ann Arbor stage, and number of extranodal sites 
implicated,  four risk groups were delineated: low risk (zero to one clinical feature), 
low-intermediate risk (two features), high-intermediate risk (three features), and 
high risk (four to five features). When applied to 2031 patients, these risk groups 
had 5-year survivals of 73%, 51%, 43%, and 26%, respectively. 
 
-Treatment- 
Surgery has an important role because biopsy of the suspected lymph-node is 
fundamental to the diagnosis of lymphoma, the histotype definition and the 
consequent choice of therapy. 
Radiotherapy is the treatment for I-II stage localized and for I stage aggressive 
lymphomas. Also it is indicated for advanced stages after chemotherapy as 
consolidation. 
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Chemotherapy is used to eradicate non aggressive lymphomas or to contain the 
disease in the indolent ones. 
 
-Survival- 
NHL can be divided into aggressive (fast-growing) and indolent (slow-growing) 
types. 
 
 - Highly aggressive lymphomas: The complete remission is superior to 70% 
The long-term survival is 30-60% depending on 
age, stage, LDH and leukemic phase  
 
- Aggressive lymphomas:                The complete remission is 60-80% 
                                                        The long-term survival is 40-50% 
 
- Mild aggressive lymphomas:         The complete remission is not superior to 40% 
 
- Indolent lymphomas:                     The complete remission is 60-70% 
 
Not responding patients and relapse: Patients not responding to initial therapy 
constitute 5-10% of cases and have bad prognosis at short time. Patients partially 
responding and patients with premature relapse can have a complete remission in 
20-35% of cases. 
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Multiple Myeloma (MM) 
Multiple myeloma (MM) is a B-cell/ plasma cell neoplasm which represents 0.8% 
of cancer cases worldwide and comprises about 13% of hematological 
malignancies (Ferlay et al. 2010; Kyle and Rajkumar, 2004). MM is principally a 
disease of older patients. Surveillance Epidemiology and End Results (SEER) 
data indicate that, in the United States, the median age at diagnosis of MM is 69 
years, with an age-adjusted incidence of 5.8 cases per 100,000 persons per year. 
About 75% of MM cases are diagnosed in persons over 50 years of age. The 
incidence of MM varies widely, ranging from 0.4 to 5 cases per 100,000 persons, 
with the highest rates in Australia, New Zealand, North America and parts of 
Europe, and the lowest rates in Asia (Parkin et al., 2005). 
The disease is characterized by infiltration of bone marrow, bones and sometimes 
other tissues by malignant plasma cells, which typically produce a monoclonal 
paraprotein. Multiple myeloma (MM) is characterized by multi-stage accumulation 
of genetic abnormalities deregulating different pathways. It can evolve from a 
monoclonal gammopathy of undetermined clinical significance (usually known as 
MGUS) which is present in about 3% of the general population over 50 years, and 
carries a risk of progression to MM of about 1% of cases per year (Kyle et al. 
2006). Initially, multiple myeloma is confined to the bone marrow (intramedullary), 
but later the tumour can be evident in extramedullary locations (such as blood, 
pleural fluid and skin) (Fig.5). Common clinical manifestations include lytic bony 
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lesions, renal impairment, anemia, hypercalcemia and immune dysfunction. 
 
 
 
Fig 5: Initiation and progression of myeloma. MGUS is an indolent, asymptomatic condition that 
transforms to myeloma in 1% of cases per annum. Smouldering myeloma lacks clinical features; by 
contrast, symptomatic myeloma has various clinical features which provide an indication that 
require treatment. Later in the disease progression, the myeloma plasma cells can be found at 
extramedullary sites and as circulating leukaemic cells. The initial deregulated cell belongs to the 
MGUS clone; however, subsequent to the development of sufficient genetic abnormalities, it 
acquires a clonal advantage, expands and evolves. At the end of this evolutionary process, at the 
stage of plasma cell leukaemia (PCL), the clone is proliferative and no longer confined to the bone 
marrow; the clone expands rapidly and leads to patient death. Cells at this stage mostly show 
chromosome anomalies and the precursor subclones will be present at low levels because of 
competition for access to the stromal niches in the bone marrow: these clones may be eradicated 
by more aggressive clones.  
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Imbalanced bone remodeling in the myeloma bone marrow is caused by increased 
osteoclast activity, together with reduced osteoblast function. Myeloma cells cause 
an increased production of osteoclast activating factors and cytokines that inhibit 
osteoblast differentiation. The unopposed osteolysis is also responsible for 
hypercalcemia. While the causes of MM remain poorly understood, factors 
affecting risk for development of the disease include age, gender and ethnic 
background, underlying immunodeficiency, exposure to radiation and family 
history of MM and other hematolymphoid neoplasms (Alexander et al. 2007). 
Several lines of direct and indirect evidence also suggest the existence of inherited 
factors, which may predispose individuals to development of MM, MGUS and 
other related cancers. 
Multiple Myeloma arises because of acquired genetic changes that occur during 
the terminal differentiation of B lymphocytes into plasma cells.The majority of MM 
cells appear to be mature, quiescent, and terminally differentiated consequently 
without long-term proliferative potential. This raises questions about which cells in 
MM patients are clonogenic and capable of proliferation. Usually, immature B 
lymphocytes after differentiation in the bone marrow, migrate as naïve B 
lymphocytes to the secondary lymphoid tissue where antigen stimulation leads to 
their proliferation. At this stage, somatic hypermutation in the IgH and light-chain 
genes gives rise to the selection of B-cell clones expressing high-affinity Igs. 
Then, cells may either leave the secondary lymphoid organs and circulate as 
memory B cells or differentiate into post-follicular plasmablasts following a switch 
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in Ig class from IgM to IgG, IgA, IgD, or IgE. Plasmablasts migrate back to the 
bone marrow for the terminal differentiation into plasma cells. 
MM cells show extensive somatic hypermutations of rearranged Ig genes which 
happen after the switch. They express markers associated with plasma cells and 
also markers associated with natural killer (NK) cells (CD56/NCAM) and T cells 
(CD28). Definitively, the exact phenotype of the clonogenic cells in MM remains to 
be established but some studies have suggested that they may be resistant to 
chemotherapy and that may persist following treatment  (Kiel,1999). 
From a genetic point of view, the majority of MM cases is characterized by 
complex chromosome abnormalities (Fig.6). 
On the basis of alterations in chromosome number, patients can be divided into 3 
groups: 
- hypodiploid/ hypotetraploid  (less than 46 chromosomes/ 75-90 chromosomes) 
- pseudodiploid (46 chromosomes with structure alterations) 
- hyperdiploid (more than 46 chromosomes) 
In particular, in around half of cases, trisomies of several odd numbered 
chromosomes occurs (in particular of chr.3, 5, 7, 9, 11, 15 and 19); remaining 
cases are characterized by a chromosome translocation, which places an 
oncogene into the immunoglobulin heavy chain gene on chromosome 14 (IgH 
translocation). The result is oncogene overexpression and dysregulated cell 
proliferation. This subtype encompasses hypodiploid and pseudodiploid MM 
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composed of high level of IgH rearrangements (localized on locus 14q32) 
generally associated with more aggressive clinical features and shorter survival.  
 
 
Fig 6. Disease stages and timing of oncogenic events. The earliest oncogenic changes are present 
in monoclonal gammopathy of undetermined significance (MGUS) and involve two minimally 
overlapping pathways, primary IgH translocations (black triangle) and multiple trisomies (white 
triangle), each of which can include a del13 pathway (grey triangle). Other karyotypic abnormalities 
and epigenetic changes can occur at all stages. 
Activating mutations of MAF (which upregulates cyclin D2, a promoter of cell cycle progression) 
appear to mark, if not cause, the MGUS to multiple myeloma (MM) transition in some cases, but 
sometimes occur during subsequent progression of MM. It has been proposed that dysregulation of 
cyclin D gene provides a unifying, early oncogenic event in MGUS and MM Late oncogenic events 
that occur at a time when tumours are becoming more aggressive include MYC dysregulation, bi-
allelic deletion of p18, inactivation of Rb, and loss or mutation of p53.  
 
The IgH (14q32) translocations can involve many different partners and often  
cause exchanges involving oncogenes. The most frequent IgH translocations in 
myeloma are t(4;14)(p16;q32), t(11;14)(q13;q32), t(6;14)(p21;q32)  
t(14;16)(q32;q23), and t(14;20)( q32;q12). 
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The t(4;14) chromosome translocation is the genetic event in MM with the most 
important clinical significance and occurs in about 15% of patients. Two genes 
located in 4p16 are dysregulated by t(4;14): MMSET (over-expressed in all 
tumours with a t(4;14)) and FGFR3 (a fibroblast growth factor receptor, over-
expressed in  about 20 % of these tumours). MMSET is a chromatin-remodelling 
factor and has a role in DNA repair. Indeed, following DNA damage MMSET is 
recruited to sites of double strand breaks (DSB) and required for recruitment of 
p53-binding protein. Approximately half of the translocation breakpoints in t(4;14) 
MM results in a truncated MMSET and then in a loss of the normal DNA damage 
response pathway. Also, MMSET has been shown to post-transcriptionally 
enhance the expression of MYC and to mediate constitutive NF-kB activation. As 
to FGFR3, the translocation appears unbalanced in up to 25% of cases, losing the 
derivative chromosome 14, which is associated with the loss of FGFR3 
expression. 
The t(11;14) is found in about 15% of patients and associated with iperexpression 
of cyclin D1; t(6;14) is associated with iperexpression of cyclin D3; t(14;16) is 
found  in about 5-10% of cases and associated with iperexression of MAF 
(transcription factor controlling the expression of interleukin-4 (IL-4) and  the 
adhesion of molecules able to enhance the ability of  tumour cells to interact with 
the BM microenvironment). The t(14;20) occurs in about 2% of patients with 
iperexpression of MAFB.  
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With the exception perhaps of FGFR3, it is interesting to note that none of the 
primary translocations causes dysregulation of strong oncogenes. 
A large number of secondary chromosome aberrations are found during tumour 
progression. These aberrations include translocations of MYC, deletions of 
chromosome 13, deletions and/or amplifications of chromosome 1, and deletion of 
chromosome 17p13, as follows: 
-A majority of MYC translocations involve an Ig locus. 
 The MYC translocations mostly are nonreciprocal translocations or insertions, 
often with the involvement of three chromosomes and sometimes with associated 
duplication, amplification, inversion, and other associated chromosome 
abnormalities. 
-An other anomaly concerns chromosome 13 (85% of cases as monosomy,15% 
as deletion). In particular monosomy of 13 is associated with poor prognosis: RB1 
gene is located in the lacking segment and its haploinsufficiency is though to 
promote tumourigenesis. A recent genome wide sequencing study identified 
mutations of DIS3 (gene of unknown function on 13q), in about 10% of MM. 13q 
deletion is associated with poor prognosis only if other cytogenetic abnormalities, 
such as t(4;14) and deletion of 17p13, are present.  
-Gain of chromosome 1q and loss of 1p frequently occur together in MM, and each 
of them is associated with a poor prognosis. MCL1 gene with anti-apoptotic 
function has been suggested as a potential driver of the adverse survival. On two 
regions of 1p potential targets associated with a poor prognosis are: CDKN2C 
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(p18INK4c) at 1p32.3 and FAM46C at 1p12. Homozygous deletion of CDKN2C 
gene (cell cycle regulator) is present in about 30 % of HMCL and about 5 % of 
untreated MM. 
-Deletion of chromosome 17p13, is the most important cytogenetic factor because 
it involves the tumour suppressor gene p53 and it is associated with negative 
treatment outcomes. Table 3 illustrates the correlations between chromosome 
anomalies and risk of MM. 
In general, genetic abnormalities alter the expression of adhesion molecules on 
myeloma cells, as well as responses to growth stimuli in the microenvironment. 
The adhesion of myeloma cells to hematopoietic and stromal cells induces the 
secretion of cytokines and growth factors, including interleukin-6, vascular 
endothelial growth factor (VEGF), insulin-like growth factor 1, members of the 
super-family of tumour necrosis factor, increasing tumour growth, survival, 
migration, and drug resistance (Palumbo A,2011). 
 
HIGH RISK   STANDARD RISK 
Hypodiploidy   Hyperdiploidy 
Del 17p   t(11;14) 
Del 13   t(6;14) 
t(4;14)   Other anomalies 
t(14;16) 
 
Table3: Correlations between the most frequent chromosome anomalies and risk of MM 
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- Classification- 
Myeloma is classified into three categories. Individuals in the first two categories 
are considered asymptomatic and do not have to receive anti-myeloma treatment 
immediately.  
•  MGUS : Considered a precursor to myeloma. Bone marrow plasma cells <10% 
and no evidence of other B-cell disorders, No related organ or   tissue impairment 
Risk of progression to malignancy:  1% per year (about 20%-25% of individuals 
during their lifetime). 
•  Smoldering or asymptomatic myeloma:  Bone marrow plasma cells >10% and 
no related organ or tissue impairment. Risk of progression to malignancy: 10% per  
year. 
• Symptomatic myeloma:  Bone marrow plasma cells or plasmacytoma and related 
organ or tissue impairment.    
 
- Clinical staging and prognosis-  
It is possible to distinguish 4 stages of the disease on the basis of bone marrow 
morphology: 
1) Mature myeloma (formed by more than 10% of mature plasmacells and less 
than 12% of immature plasmacells). 
2) Intermediate myeloma (all myelomas which not reenter in the other 
subtypes) 
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3) Immature myeloma (formed by more than 12%of immature plasmacells and 
less than 10% of mature plasmacells). 
4) Plasmoblastic myeloma (formed by more than 2%of plasmoblasts) 
Although the introduction of novel therapeutic agents has transformed the outlook 
for many patients, myeloma remains a heterogeneous disease. Some patients will 
live for more than eight years after diagnosis, whereas a subset with high risk 
disease will die within 24 months.  
 
-Treatment- 
Patients with MGUS and asymptomatic myeloma are observed but not treated 
until they develop symptomatic myeloma. 
No intervention has been found to delay or prevent the progression of MGUS to 
myeloma. 
Most of MM patients respond to initial treatment and enter a period of disease 
stability, which is generally associated with good quality of life. Because of the lack 
of curative treatment, relapse is inevitable, but at least half of patients respond to 
chemotherapy a second time, using similar or different drugs. Subsequent 
relapses become increasingly less responsive to treatment, until refractory end 
stage disease ensues, sometimes with extramedullary manifestations and 
cytopenias. The approach to treating newly diagnosed symptomatic myeloma 
depends on age and comorbidities. Initial chemotherapy regimens aim to achieve 
the deepest response with the lowest toxicity, and for patients who are young 
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(generally <65 years) and fit enough, this is consolidated with high dose 
chemotherapy and autologous stem cell transplantation. 
Older patients, or those with serious comorbidity, who not fit enough to undergo 
autologous transplantation are treated with chemotherapy only. A second 
autologous stem cell transplant may be considered in patients who are young and 
fit enough and who achieved a long (≥18 months) remission after first transplant. 
 
-Survival- 
Multiple myeloma is a disease not eradicable. The survival can vary between 
some months and some years with a median of 2.5-3 years for patients treated 
with conventional therapy. The latest increasing use of high doses therapy and the 
introduction of new drugs have produced a significant improvement in survival and 
in  free-disease time. 
 
Genomic instability and cancer 
Genomic alterations are important causes of cancer development. Typical clonal 
expansion of tumour is the result of progressive accumulation of genomic 
changes. This results in the loss of tumour suppressor functions, in the activation 
of oncogenes and/or in the generation of fusion genes with oncogenic potential 
and they lastly lead to the phenotypes of malignant cancer cells. 
Changes which could occur are simple mutations, genomic rearrangements and 
number and structure chromosome anomalies. 
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In the last few years a new phenomenon, termed chromothripsis has been 
revealed by using  combination of next-generation DNA sequencing, single 
nucleotide polymorphism array analyses and bioinformatics methods. 
Chromothripsis indicates chromosomes carrying dozens to hundreds of clustered 
rearrangements acquired in the most of cases in a single catastrophic event in a 
cancer cell (Stephen PJ et al, Cell 2011). These rearrangements derived from 
distinct chromosomes or chromosome regions fragmented into many segments 
some of which joined together by DNA repair mechanisms in ways that did not 
necessarily relate to their original order or orientation in the progenitor 
chromosome. The stamp of chromothripsis can be described in at least 2%–3% of 
all cancers, across many subtypes, including hematopoietic malignancies like 
chronic lymphocytic leukaemia, lymphoma and multiple myeloma (Fig7). 
The agent of this physical chromosome damage is unknown. We wonder if this 
phenomenon may be found also in NHL and MM patients.  
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Fig 7: Example of chromosome catastrophe might break the chromosome into many pieces joined 
back together haphazardly  
Hematopoietic stem cell transplantation 
The discovery of CD34 as a stem cell marker, absent in more differentiated cells,  
has simplified the haematopoiesis study, revolutionized the assessment of 
progenitor cells present in the peripheral blood stem cell graft and improved the 
parameters to perform hematopoietic stem cell transplantation. Hematopoietic 
stem cell transplantation (HSCT) is the transplantation of multipotent 
hematopoietic stem cells representing an effective treatment strategy for a variety 
of hematologic malignancies. In fact, the vast majority of allogeneic HSCT (70%) 
are performed for hematologic diseases and in particular: acute myeloid leukaemia 
(AML, 32%) and acute lymphoblastic leukaemia (ALL 16%), myelodysplastic 
syndromes (MDS 16%) and non Hodgkin lymphoma (NHL 9%). In particular, only 
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diseases with poor prognosis (<50% survival at 5yrs with conventional treatment) 
are currently indications for allogeneic transplantation. On the other hand, the 
most frequent indications for autologous HSCT (ASCT) in Europe are plasma cell 
myeloma (PCM), HL and the majority of patients with NHL. In particular HL 
patients receive this treatment once they have relapsed after chemotherapy. 
Sources of hematopoietic stem cells for transplantation are different: 
• Bone marrow: the major source of cells for allogenic transplant. 
• Peripheral blood: now the most common source of stem cells for HSCT. 
They are collected from the blood of patient (in the case of autogenous 
transplantation ) /donor (in the case of allogenic transplantation) through a 
process known as apheresis. 
Autologous transplantation (ASCT) 
The collection of adequate numbers of HSCs is a prerequisite for proceeding to 
autologous transplantation; however, the optimal mobilization regimen remains 
unknown for moving and  procurement of autologous HSCs from the bone marrow 
to the peripheral blood. A variety of mobilization strategies are currently used, 
including growth factors alone or in combination with chemotherapy. The most 
used growth factors are the recombinant granulocyte-colony stimulating factor (G-
CSF) analogs. The harvest of peripheral HSC is made during the process of 
apheresis through cells separators and then cryopreserved. Counting of CD34+ 
cells in peripheral blood allows to estimate the number of collected stem cells. 
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To eradicate the disease and to create space in the bone marrow cavity for stem 
cell proliferation all patients are exposed to the conditioning regimens. Indeed 
chemotherapy is added to improve CD34+ cell yield and for in vivo purging of 
mobilized tumour cells to reduce tumour burden (although there are limited 
supportive data). This is high doses chemotherapy after which normal 
hematopoiesis is irreversibly destroyed. The aplastic phase lasts 10-15 days 
during which the patient cannot produce erythrocytes, platelets and leucocytes 
and he is exposed to the infection risk. After 24-48 hours from the conditioning 
regimens the collected stem cells are re-infused to the patient through a normal 
blood transfusion. Using their migration ability, stem cells reach the depleted 
niches and there take root to build up the physiologic bone marrow.  
For ASCT, risks include the short and long term toxicities of the high dose 
treatment during the preparative regimen. Consequences may be organ damage 
and risks of infection and bleeding associated with the marrow aplasia.  
Indications for autologous transplantation: 
Hematologic neoplasms treated with autologous stem cells are: 
 
- Acute and chronic leukaemia (in acute myeloid leukaemias which present high 
risk of relapse disease, the autologous transplantation could be used as 
consolidation therapy for patients in first complete remission. In acute lymphoid 
leukaemia it is used after relapse) 
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   -Lymphoma (in which it is employed as first therapy but also after relapse after 
complete remission) 
   -Multiple Myeloma (in which it is used in first line of treatment) 
 
 
 
 
Table 4. Indications for transplantation of hematopoietic stem cells in adults based on the EBMT 
recommendations. Abbreviations: aaIPI – international risk indicator adjusted for age, CR >1 – 
consecutive remissions achieved after relapses, S – standard indication based on clinical trials, CO 
– justified indication, but requiring confirmation in clinical studies, CR1 – completely first remission, 
D – experimental use in clinical studies, NR – generally not recommended (Hołowiecki, J, 2008) 
 
Limitations, consequences and perspectives: 
The autologous transplantation is performed in patients up to 70 years to reduce 
the risk of rejection and mortality presented by the allogenic transplantation. 
Major limitation of this kind of transplantation consists in the relapse of disease 
which can be either caused by residual therapy-resistant cancer niches in the 
patient or by contaminating cancer cells within re-infuses stem cells (Rahman M, 
2010). In order to eliminate contaminating cancer cells and to protect the normal 
HSPCs necessary for subsequent hematopoietic reconstitution, several cancer cell 
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“purging” strategies have been tested over the last three decades. Results are still 
conflicting. It is still not possible to know which purging technique could be used 
with good results (Yang et al., 2011). 
Also, it has been hypothesized that the use of growth factors to mobilize cells from 
bone marrow to peripheral blood could promote the mobilization of cancer cells 
also (Moreb et al., 2011). 
Factors affecting the outcome of autologous transplantation are age of patient, 
stage of disease and number of previous treatments.  
Encouraging results are obtained  in acute myeloid leukaemia  patients.  
In acute lymphoid leukaemia, results are more disappointing since an high 
percentage of relapse is observed after the transplantation.  
In myeloproliferative and lymphoproliferative syndromes, relapse is inevitable; in 
that cases the goal of ASCT is the survival extension and the enhancement  of life 
quality. 
Studies are on going to associate autologous and allogenic transplantation in 
absence of myeloablative conditioning to cure multiple myeloma and chronic 
lymphatic leukaemia.  
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AIM OF THE STUDY 
 
 
The therapy of various hematologic diseases consists of high dose of 
chemotherapy/radiotherapy associated with autologous stem cells transplantation. 
The aim of this study is to correlate chromosome alterations with the pathology 
progress and to highlight significant regions for prognosis and transplantation. The 
hypothesis to confirm is that growth factor stimulation in combination with 
chemotherapy could influence the chromosome stability of hematopoietic 
precursors; this could cause the isolation of pathologic clones then re-infused 
during the transplantation. 
Diseases analyzed in this study are lymphoma and multiple myeloma. All 
evaluated patients have been submitted to chemotherapy, G-CSF mobilization, 
apheresis and transplantation. 
Stem cells have been purified and frozen at -196C to preserve vitality and stability 
during the time. In this phase samples have been collected to perform genetic 
analysis: CD34+ cells have been isolated and DNA extracted from them.  
a-CGH analysis have been performed and the observed imbalanced chromosome 
anomalies confirmed by FISH. Furthermore a clinical follow-up study has been 
accomplished in all patients considering the haematic recovery after stem cells re-
infusion, the survival without disease and the appearance of second neoplasms. 
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Future research consists in the extension of clinical records to obtain statistical 
relevance. 
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MATERIALS AND METHODS 
 
Patients affected by hematopoietic diseases following treatments at the medical 
oncology department of Ospedale di Circolo Fondazione Macchi of Varese and 
offering material for this study are: 
Patient             Year of birth            Disease 
1.   1941   MM 
2.   1980   HL 
3.   1962   MM 
4.   1980   NHL 
5.   1954   HL 
6.   1952   MM 
7.   1961   NHL  
8.   1942   HL 
9.             1970   HL 
10.   1976   HL 
11.             1943   MM 
12.             1944   NHL 
13.   1950   NHL 
14.   1955   NHL 
15.   1964   MM 
16.   1948   MM 
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17.   1977   Theratoma 
18.   1950   MM 
19.   1981   HL 
20.   1959   NHL 
21.   1944   MM 
22.   1946   NHL 
23.   1959   MM 
24.   1965             MM 
25.   1951             MM 
26.   1946   MM 
27.   1954   NHL 
28.   1961             NHL 
29.   1948   NHL 
30.             1958   NHL 
31.             1965   NHL 
32.   1967   MM 
33.   1938   NHL 
34.   1952             NHL 
35.   1967             HL 
36.   1945   NHL 
37.   1954   NHL 
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Since 2009 37 mobilizations of hematopoietic stem cells have been realized 
and an aliquot of 1.5 ml of  CD34+ has  been collected to the research. 
Between them 16 are NHL, 13 are MM, 7 are HL and 1 is a malign therathome. 
18/37 patients have not been re-infused. 
-Stimulation protocol- 
Patients have been treated with  induction-chemotherapy and mobilized by G-
CSF 5ug/Kg twice per day. To determine the recovery of bone marrow, 
leucocytes concentration has been estimated by hemocromo-cytometric 
analysis using SYSMEX XT-2000i. Also, to establish the number of stem cells 
ISHAGE cytometric assay has been applied by taking advantage of membrane 
proteins expression as CD34 and CD45.  
The data were strongly heterogeneous. 
-Apheresis- 
Strategy of stem cell collection from peripheral blood consists in: 
-Accurate evaluation of patient through examinations as blood count, 
coagulation test, thorax radiography, electrocardiogram and echocardiogram. 
- Estimation of stem cell number by using cytometric analysis to individuate 
when to accomplish the apheresis. 
-Monitoring arterial pressure and cardiac frequency 
- Use of systems to limit platelets, erythrocytes and lymphocytes contaminations 
in the final product which could cause a lesser engraftment of  transplantation. 
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In particular, apheresis procedures consist in the processing of two haematic 
volumes calculated considering 65 ml per Kg of patient as standard.  
Patients have been connected to the cells separator Fresenius COM.TEC 
(Fresenius  kabi). 
Cells have been centrifuged and stem cells were found in the middle phase of 
the gradient. 
Number of cycles for each patient depends on blood volume and it can vary 
between 16 and 30, giving different cell properties at final product. 
-Cells Freezing- 
-Weigh sacs and collect an aliquot to determine leucocytes and stem cells 
concentrations 
-Add equivalent volume of physiologic/ albumin 7% 
-Centrifuge sac 1100RPM , 25min, 20degree 
-Prepare solution of recipient plasma 20%DMSO on ice 
-Calculate final volume of sac considering leucocytes and stem cells 
-Eliminate supernatant and add equivalent volume of plasma and 20%DMSO  
-Freeze cells by decreasing 1 degree per minute until -7C, plateau for 5 minutes 
at -7C, decreasing 3 degrees per minute until -30C and fast decreasing of 5 
degrees per min until -100C.  
-Preserve cells in liquid nitrogen 
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-Cells Thawing - 
-Slowly thaw cells at 37C 
-Add 40ul heparin and 10ml of RPMI1640 
-Centrifuge at 2000 RPM for 10 minutes 
-Take out supernatant and add 10 ml RPMI1640 
-Centrifuge at 2000 RPM for 10 minutes 
-Take out supernatant and add 6ml of RPMI1640/ 2% pen-strept/10% FCS 
-Labelling- 
- Add mAb CD45/CD34 and 7AAD  
- Incubate 25min, at dark, at RT 
 
Sorting with BD FACS ARIA II 
- Set up stream: DROP 1 ~180; 7 GAP; frequency ~88; nozzle 70 µm; 
- Use ISHAGE methods to acquire; 
- Set up threshold for debris as 50.000 on SSC channel; 
- Define stem cell populations according to these characteristics: 
  dimensions of lympho monocytes on SSC/FSC channels, intermediate 
expression of CD45, strong expression of  CD34; 
- Set up flow rate not exceeding  20.000 events per second; 
- Sorting stem cells with purity above of 90 %. 
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Array comparative genomic hybridization (a-CGH) 
The aCGH is a high-resolution detection of DNA copy number aberration. 
The assay consists in sample and reference DNA extraction, quantification 
labelling and mixing in the hybridization, then in washing and signal detection. 
Using an image-processing software, chromosome regions with an abnormal 
sample: reference ratio are found  (with loss or gain of DNA sequences).  
-DNA extraction- 
DNA of CD34+ cells sorted by FACS has been extracted by using Qiagen 
Flexigene Kit #51204 (Qiagen Inc., Valencia, CA – USA) with some specific 
expedients.  
-300.000-1.000.000 cells of each FACS separation have been centrifuged at 
300g for min.; 
- Supernatant has been eliminated and cells re-suspended in FG1 buffer; 
- Lysis buffer (mix of FG2 buffer and Protease) has been added; 
- Sample has been vortex 3 times for 5sec. and incubated for 15min at 65°C; 
- DNA precipitation has been carried out by using TR Iso-propanol; 
- Sample has been centrifuged  for 60min, 4°C at 20.000 x g; 
-After supernatant elimination, samples were washed in 70% ethanol and 
centrifuged for 15 min, 4°C at 20.000 x g; 
- Pellet has been dried for 5-10 min;  
- DNA has been re-suspended in FG3 buffer and incubated for 15 min at 65°C; 
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-DNA quantification- 
DNA has been quantified by using Qbit assay (Invitrogen # Q32857, Invitrogen 
Ltd (European Headquarters), Paisley PA4 9RF, UK) and BR (#Q32850) based 
on the average of 3 readings of each sample. The usual DNA concentration 
was between 25 e 35 ng/μl. For lower concentrations DNA has been  amplified 
through WGA2 KIT (Sigma-Aldrich Corporate - St. Louis, MO – USA). 
 
-DNA quality control- 
The quality of extracted DNA has been verified through  electrophoresis on 
1,2% agarose/ TAE gel and spectrophotometric method by using Nanodrop ND-
1000 (Thermo Scientific – Nanodrop division, Wilmington, DE – USA). 
Best parameters of Absorption  for 260/280 are 1,8-2.0 and for 260/230 are 1,9-
2.2. 
 
 -DNA Labelling- 
DNA of reference and  patient have been prepared for a-CGH hybridization 
following Agilent Enzymatic Genomic Labelling protocol version 6.2. Briefly:  
-500 ng of each DNA have been digested with AluI e RsaI restriction enzymes 
(Promega Corporation Woods Hollow Road Madison, WI – USA) for 2h at 37°C;  
-The enzymes have been  inactivated  at 65°C for 20’;  
-Obtained fragments (100-500bp) have been labelled in random priming with 
Agilent Genomic DNA Enzymatic labelling KIT #5190-0449 (Agilent 
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Technologies, Inc, Santa Clara CA – USA) ,then denatured at 95°C for 3min 
and incubated for 5min on ice;  
-Labeling mix has been prepared. Patient DNA has been labeled by using 
dCTP-Cy5 and reference DNA by using dCTP-Cy3; 
-The labeled mix has been added to DNA 
-The reaction has been incubated at 37C for 2h and inactivated at 65C for 10 
min; 
-The purification of labeled fragments has been performed through columns Kit 
Amicon Ultra 0.5 #UFC503096 (Millipore Corporate Headquarters, Billerica, MA  
– USA). After TE addiction and centrifugation at 14.000g for 10min, the eluted 
was eliminated (twice); 
-Labeled purified DNA has been recovered by centrifugation at 1.000g for 1min; 
-The efficiency of labeling reaction has been checked through Nanodrop 
spectrophotometer; 
-Reference and patient labeled DNAs have been mixed and added with 
blocking solution, hybridization solution (Agilent #5188-5220) and Cot-1 DNA 
(Invitrogen Ltd  - European Headquarters, Paisley PA4 9RF, UK). 
-The hybridization mix has been denatured at 95C for 3min, placed at 37°C for 
30min for pre-annealing reaction and then placed with oligonucleotides spots 
whole genome 244K Agilent G4411B slide in a hybridization chamber at 65°C 
for 40h; 
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-The array slide has been washed 5min in the solution 1 at room temperature 
and 1 min in the  solution 2 at 37°C (Both the solutions are from Agilent). 
-The array was scanned by using Agilent scanner with a resolution of 5μm. 
Fluorescence analysis was performed by Agilent Feature Extraction 9.6. 
software; 
a-CGH profile has been interpreted by using Agilent Genomic Workbench 5.0 
software and ADM2 algorithm (threshold 6.0). 
Computer analysis  
Data analysis has been performed comparing all patients with benign copy 
number variants (CNVs) present  in http://projects.tcag.ca/variation/ site. This 
site consists of all identified sequences with altered number of copies in healthy 
subjects. Since compared regions were copious, an house software was made 
to easily permit the alignment. The data allowed to exclude sequences which do 
not represent pathologic markers since already present in literature and 
highlighted  as normal polymorphic alterations (bCNV). 
Fluorescence in situ hybridization (FISH)  
The Fluorescence in situ hybridization allows the localisation of a specific 
sequence of DNA on fixed chromosomes, nuclei or tissue samples obtained 
from fresh or cryopreserved biologic material as blood, biopsy and amniotic 
fluid. 
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The assay is based on the reversible denaturation DNA property and  it consists 
in the binding of a fluorescence probe and the DNA complementary sequence 
of the sample; in this way the chromosome region of interest results easily 
identifiable at fluorescence microscopy. 
FISH technique consists in:  
-Ageing of samples: low salty solutions increase the probe accessibility to 
targets sites. 
-Denaturation of probe and target: conditions change with probe and sample. 
The correct-one can be found acting on temperatures (between 70 and 80 C) 
and denaturation time (between 2 and 5 minutes). It is frequent the use of 
denaturation solutions containing formammide (to reduce the double chain heat 
stability) and don’t resort too high temperatures. 
-Hybridization: Conditions for probe-target heteroduplex formation are important 
and in particular the probability to maintain heteroduplex containing wrong 
couples is lower when conditions are stronger (low salts concentration, high 
temperature, denaturation agents). 
-Wash: the fluorescent probe can bind incompletely sequences with lesser 
homology. The resulting less stable hybrids can be dissociated intervening on 
temperature, time and solution composition of washing. 
Samples can be observed with a fluorescence microscope (LeicaDMRA). 
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The BACs (Bacterial artificial chromosome) probe used in this study are 
RP11-596C4 and CTD-2130L6, specific for a small region in chr2 p16.1 
and produced in our laboratory by using BAC Phase Prep Kit (Sigma). 
Once isolated, BAC has been labelled by Nick Translation. 
-Nick translation- 
This assay is based on DNase I ability to introduce nicks on single chain of 
DNA and on  E. Coli DNA Polymerase exonuclease 5’-3’ ability to repair 
nicks, re-polymerizing DNA partially. Therefore, digoxigen-11-dUTP 
labelled nucleotides (Roche Biochemicals) in the  buffer are incorporated 
during the reaction. For Nick Translation reaction NICK TRANSLATION 
KIT (Roche Biochemicals) has been used. After incubation for 2h at 15 C, 
Cot-1 DNA (Roche Biochemicals) and Salmon Sperm DNA have been 
added in excess to saturate repetitive sequences in the probe.  
Then DNA has been precipitated and re-suspended in formammide, SSC 
and Dextran sulphate solution. 
-Preparation of slides- 
Part of sorted cells has been re-suspended in fixative solution and gently 
dropped on slides. For good FISH results is important to obtain intact nuclei in a 
good concentration. Slides have been treated with 2XSSC solution for 30’ at 37 
C  and dehydrated in alcohol 70%-85%-100% at RT. 
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-Denaturation, hybridation and signal amplification.- 
BACs have been denatured at 70C for 10’, then pre-annealed at 37C for 
1h 30’. Meanwhile slides have been denatured at 72C for 5’ in 70% 
formammide/2XSSC solution and dehydrated in alcohol 70%-85%-100% 
at RT. Hybridization was performed  at 37C O/N. Three cycles of 
amplification have been done by using anti-DIG for 60’, anti-Mouse for 45’ 
and anti-Rabbit for 45’again at 37C. Nuclei have been contrasted by DAPI 
and Propide Iodide. Slides have been observed with fluorescence 
microscope (Leica DMRA) and analysis performed by using Q-FISH Leica 
Imaging System Ltd software. 
 
Cytogenetics and molecular genetics data  
Cytogenetic analysis have been realized in multiple myeloma, mantel and 
follicular lymphoma. 
About multiple myeloma, in particular at the onset when the percentage of 
plasmacells is not high, it  is important to select the clone to be analyzed 
by FISH. The selection is accomplished by immunomagnetic separation 
on column by using CD-138 as antigen. FISH have been performed to 
check: 
-rearrangements in 14q32 
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-t(11;14)(q13;32) and the consequent increase of CCND1 expression 
-t(4;14)(p16.3;q32) which involves MMSET(multiple myeloma set domain) 
and FGFR3 (fibroblast growth factor receptor 3) 
-monosomy of 13 and deletion of 13q who represent the majority of 
cytogenetic alteration in MM 
-17p13 deletion which involves p53 deletion 
Clinical follow-up 
Since 2009 mobilized patients have been 37; between them 18 have not 
been re-infused and consequently excluded from this study. Left patients 
have been analyzed considering: the immediate effect of stem cells 
reinfusion, the values of leucocytes, platelets, haemoglobin and 
haematocrit at 1,6,12 months after reinfusion. Also, disease free survival 
(DFS= time between the transplantation and the progression of pathology) 
and overall survival (OS) have been evaluated. 
Patients subjected to pre-transplantation cytogenetic analysis have been 
studied in the same way after the ASCT to verify the presence of old or 
new mutations. Data of follow-up have been compared to cytogenetic 
analysis. 
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RESULTS 
Apheresis optimization 
All patients have been subjected to chemotherapy and to one or more 
apheresis procedures. 
As indicated in the fig 8, first effect of chemotherapy is the aplastic state 
which reaches the lowest level at day 10 in peripheral blood. Later, G-CSF 
causes stem cells mobilization at day 14 and the retake of normal 
haematopoiesis. 
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Fig 8: Scheme of bone marrow aplasia and stem cells mobilization after chemotherapy and 
G-CSF administration. 
As indicated in material and method section, final product of apheresis could have 
different cell properties. 
Indeed, volumes of apheresis resulted included between 510 mL and 55 mL with a 
mean of 255 mL. 
Furthermore, concentration of white-cells in the peripheral blood at the 
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moment of apheresis caused different concentrations of leukocytes in the 
apheresis product included between 257,000,000 cells/mL and 36,500,000 
cells/mL with a mean of 158.780.000 cells/mL and a median of 152,000,000 
cells/ mL. Freezing, thawing and labelling stem cells optimization 
Cells obtained  by apheresis are stocked  at -196 C. 
To this aim cells are transferred in a sac with physiologic solution, 7% albumin and 
centrifuged. Obtained pellet is re-suspended in 10% DMSO. Concentration of 
leukocytes can’t exceed the limit of 200,000,000 cells/mL to maintain cell vitality 
during freezing procedure. 
The data were included between 255,000,000 cells/mL and 28,700,000 cells/mL 
with a mean of 169,100,000 cells/mL and a median of 175,800,000 cells/mL. So in 
the case of 255,000,000 cells/mL the limit was overstepped determining a 
decreasing of vitality at 77% against the mean of 90%. 
Also the concentration of stem cells in the collected samples presents different 
values due to the variability in the number of cells in the peripheral blood at the 
moment of the draw and included between 21,000,000 cells/Kg and 1,400,000 
cells/Kg with a mean of 6,800,000 cells/Kg and a median of 5,400,000 cell/Kg. 
Using these data a thawing protocol was developed to permit a maximum cell yield 
necessary for a-CGH experiments (for which 500ug of DNA and 300000 nuclei 
approximately are essential). 
Cells have been thawed by using RPMI-1640. Heparin has been added to prevent 
aggregated  formation at a final concentration of 4%. 
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After washed twice cells have been re-suspended in RPMI 1640 medium/serum 
5%/ pen/strept 2%. This expedient permitted to higher the efficiency of sorting 
obtaining a purity major of 90% and in some cases collecting a great number of 
cells passing the million of CD34+cells. 
This study leaded to the selection and the quantification of CD34+ cells (Fig 9). 
 
 Fig 9: ISHAGE methods to define stem cell concentration 
Obtained data manifest high heterogeneity in leukocyte counting and in  stem 
cell concentration. In effect, analyzed patients show values of CD34+cells/µl 
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between 26 and 385. This variability confirms the bone marrow 
compromission after chemotherapy and mobilization (Table 5). 
 
Purity% Number of sorted CD34+ cells 
Patient 1         91.00  268,219 
Patient 2         90.00  447,491 
Patient 3         96.00  457,943 
Patient 4         95.00  1,003,124 
Patient 5         89.00  653,591 
Patient 6         94.00  818,860 
Patient 7         96.00  1,049,609 
Patient 8         98.00  503,380 
Patient 9         95.00  964,670 
Patient 10         92.00  626,865 
Patient 11         92.00  1,065,338 
Patient 12         92.00  800,654 
Patient 13            nd  326,977 
Patient 15         94.00  305,696 
Patient 16         93.00  323,179 
Patient 18         89.00  1,045,722 
Patient 21         93.00  468,945 
Patient 27         98.00  657,948 
Patient 28         92.00  525,853 
Patient 29         89.00  557,592 
Patient 30         89.00  866,348 
Patient 31         91.00  923,179 
Patient 35         89.00  466,348 
Patient 36         91.00  323,179 
   
MAX         98.00  1,065,338 
MIN         89.00  268,219 
MEAN         92.52 643,779 
Table5 :  Recapitulatory data of sorting. 
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Array-CGH (a-CGH) 
The DNA from CD34+ cells sorted was extracted. 
The DNA and the optimal labeling of hybridization quality have been evaluated 
through the red and green fluorescence ratio (Fig.10) 
Results allow to consider as significant all the alterations that have been found. 
 
  
Fig 10: Intensity of signal distribution on green and red channels (Agilent Genomic Workbench 5.0)   
 
The data from a-CGH have been filtered by ADM2 algorithm which confers a 
statistic significance to each present probe in the slide based on the gap from the 
zero line. In order to evidence the aberrations, the fixed parameter was of 5 
consecutive probes (around 30000 bp of mean) with significant deviation for 
ADM2. Furthermore, the alteration has to be not inferior to 10% of cells in the 
sample (Valli R. et al, 2011). Fig.11 shows an example of segmental loss of 
chromosome 18 in 36.4% of cells. 
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 Fig.11: Example of imbalance found by a-CGH : chromosome 18 loss in 36.4% of cells. 
 
Out of 37 patients, 24 have been processed for a-CGH. 
Obtained a-CGH data showed a clear difference in the number of found 
imbalances. Indeed the majority of patients had a mean of 20.3 alterations but 3 
patients have more than 100 imbalances. Overall, data showed a maximum of 525 
altered regions and a minimum of 15 with a mean of 65.53 and a median of 27.  
The hypothesis is that alterations predisposing to the pathology could be present 
in HSCs. Therefore, common altered sequences have been searched among the 
recurring alterations of patients affected by the same disease. Patients have been 
divided in two groups, those affected by MM and those affected by Lymphoma (HL 
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and NHL). 453 sequences of patients with lymphoma and 661 sequences of 
patients with myeloma have been analyzed. The comparison between different 
patients showed copy number polymorphisms and interesting regions not mapping 
in the database but altered in at least two patients. 
Found data showed 26 imbalances in a single patient which need in-depth 
analysis and the same imbalances not mapping in CNV database in 2/8 Multiple 
Myeloma patients (see Appendix). 
In the case of Lymphomas, obtained data showed 17 imbalances in a single 
patient and common imbalances region in 10/16 patients on chromosome17 as 
expected for the pathology (Chui DT et al, 2003). 
The most significant alterations were: 
In patient (2) a deletion of 4.34MB in 14.5% of cells has been found on 
chromosome 2 in p16.1 (start: 56.586.512, end: 60.932.053 bp) and including part 
of REL oncogene associated to rare forms of myelomas and lymphomas (Gilmore 
and Gerondakis, 2011) (Curry et al., 2009) (Fig.12).  
Patient (3) presents a duplication of 16.08Mb on chromosome 11 between q12.2 
(start: 60.517.445 bp) and q13.4 (end: 76.600.804 bp) bands in 12.38% of cells 
and including CCND1 gene often rearranged or duplicated in myelomas (Fig.13).  
Patients (8), (9), (10), (27) and (30) showed imbalances (duplications or deletions) 
in q32.31-q32.33 region of chromosome 14, containing heavy chain genes of 
immune globulin cluster often rearranged in lymphomas and myelomas (Fig.14). 
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All these patients are affected by lymphoma and in particular (8), (9), (10) are HL , 
(27) and (30) are NHL.  
                                          Chr2 
a 
  b 
 
Fig12: a-CGH results of patient (2).(a) Deletion of short arms of chromosome 2 at band p16.1 is 
highlighted (blue square); (b) part of REL gene is included in the deletion region (blue square). 
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                                     Chr11 
a 
 
 b 
 
Fig13: aCGH results of patient (3) 
(a) Amplification of long arms of chromosome 11 at band q12.2 and q13.4 is highlighted (grey 
square); (b) part of CCND1 gene is included in the amplification region (grey square). 
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                                       Chr 14 
a 
b 
Fig14: aCGH results of patients (8, 9,10, 27 and 30). 
(a) Imbalances of long arms of chromosome 14 in q32.31-q32.33 region is highlighted (grey 
square). (b) Enlargement of q32.31-q32.33 region. (Patient 8: blue line, patient 9: pink line, patient 
10: yellow line, patient 27: brown line, patient 30: green line). 
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                                       Chr1                                                    Chr11 
                              a                                                                    b 
Fig15: aCGH results of patient (1): example of the high number of imbalances found. 
(a) Ideogram of chromosome 1; (b) Ideogram of chromosome 11. Numerous picks corresponding 
to imbalances with variable dimensions are present and highlighted (blue square). 
 
In patients (1), (8) and (9) the number of imbalances found by a-CGH was much 
bigger than others with a number of alterations of 525 in patient (1) (see fig 15), 
128 in patient (9) and 103 in patient (8) where the mean for the other patients was 
25.57 (min value: 15 in patient 10; max value:37 in patient 29). 
In patients 4, 5, 6, 7, 11, 12, 16, 28, 29 and 31 no imbalances have been found 
trough a-CGH 
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For patients 13, 15,18, 21, 35 and 36, the quality of material was not good for a-
CGH analysis. 
To confirm a-CGH data, FISH or real-time PCR would be used. 
Since in this study imbalances are at low clonality (around 10%), the former is the 
best technique to consider. 
In patients (8), (9), (10), (27) and (30), presenting imbalances on chr14, was not 
possible perform FISH because of the presence of a large duplicon in 14q32.31-
q32.33 region which could produce false positive. Indeed, duplicons are 
chromosome-specific low-copy repeats whose occur in multiple regions of the 
human genome.  
It is known that  homologous recombination between different duplicon copies by 
the process of “Non Allelic Homologous Recombination (NAHR)” leads to 
chromosome rearrangements, such as deletions, duplications, inversions, and 
inverted duplications (Ji Y. et al, 2000). These recombinations bring to human 
genetic disorders and can be implied in translocation events in heavy chains of 
IgH found in some of lymphoma and myeloma. Furthermore, it is known that 
apparently balanced events as translocations could carry genomic imbalances 
(Baptista J. et al, 2008). 
Therefore, the presence of imbalances found on chr14 by a-CGH could be 
correlated to this kind of translocations.  
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In patient (2), presenting imbalances on chr2, FISH was first performed by using   
RP11-596C4 probe, specific for p16.1 region. Because of background this BAC 
was not optimal. On the other hand, the second probe CTD-2130L6 confirmed a-
CGH data showing deletion of 2 p16.1 in 12% of cells (Fig.16). 
For patient (3) not enough material was available the number of cells was not 
enough to carry out the FISH.  
 
      
Fig 16: Deletion of 2 p16.1 region shown by FISH analysis  
Cytogenetic analysis 
Cytogenetic analysis and molecular cytogenetic on  pathologic lymph node biopsy 
have been performed in the Laboratory of Cytogenetic at the Department of Clinic 
Pathology of Ospedale del Circolo, Fondazione Macchi in Varese (table 6) 
12 patients (10 affected by MM, 1 by NHL and 1 by HL) have been analyzed . 
7/10 patients with MM presented normal karyotype  46,XX/XY. 
3/10 patients with MM presented chromosome imbalances and in particular 
Patient 11: 47,XY/46,XY,del(6)(q22qter);  
Patient 6:46,XY/45,XY,del(6)(q23q25),-17; 
Patient 3: 46,XY,del(6)(q23q25); 
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The more frequent alteration is the monosomy of chromosome 13 presents in 4 
patients, then the amplification of CCND1 in three patients, the loss of p53 and the 
amplification of IgH  gene in one patient. 
The patient affected by mantle-cell NHL showed normal karyotype with 
translocation t (11;14) in 14% of nuclei, loss of ATM gene in q22-23 region of 
chromosome11 in 52% of nuclei. 
  Pathology Karyotype FISH 
      
Patient 1 MM 46,XY Monosomy 13 (total or partial) 
  MM 46,XY Neg 
  MM 46,XY Neg 
Patient 3 MM 46,XY Neg 
  MM 46,XY IgH rearrangement (3%) 
    IgH/CCND1 rearrangement (3,3%) 
  MM 46,XY Neg 
  MM 46,XY,del(6)(q23/q25) IgH rearrangement (3,2%) 
After transpl. MM 46,XY,del(6)(q23/qter) Neg 
  MM 46,XY CCND1 amplification (83%) 
  MM 46,XY CCND1 amplification (16%) 
  MM 46,XY Monosomy 13  
Patient 6 MM 46,XY Neg 
  MM nd Neg 
  MM 
46,XY/45,XY,del(6)(q23q25);-
17 Neg 
  MM 46,XY Neg 
Patient 11 MM 46,XY,del(6)(q22/qter) Neg 
  MM 46,XY Neg 
  MM 46,XY Neg 
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 Pathology Karyotype FISH 
Patient 13 NHL 46,XY IgH/CCND1 rearrangement (14%of) 
    nuclei; loss of ATM 52%of nuclei 
Patient 15 MM 46,XX Monosomy 13 in 75% of nuclei 
  MM 46,XX Neg 
  MM 46,XX Neg 
Patient 16 MM 46,XY Neg 
  MM 46,XY Neg 
  MM 46,XY Neg 
Patient 18 MM 46,XX Monosomy 13 in 88%  
  MM 46,XX Monosomy 13 in 97%  
  MM 46,XX Monosomy 13 in 94,5%  
Patient 19 HL nd Nd 
Patient 24 MM 46,XY Neg 
  MM 46,XY Neg 
  MM 46,XY Neg 
Patient 25 MM 46,XX Loss of 13q14 in 10,5% of nuclei 
  MM 46,XX Neg 
  MM 46,XX Neg 
Patient 26 MM 46,XY 
Loss of p53 in 41% of 
nuclei;monosomy13 in 88,4% 
  MM 46,XY CCND1 amplification  
 
Table6: Results of cytogenetic analysis 
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Clinical follow-up 
The distribution of different diseases of the 37 mobilized patients is shown in fig 
17. 
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Fig 17: Distribution of diseases of evaluated patients in the follow–up; MM: Multiple Myeloma, HL: 
Hodgkin Lymphoma, NHL: Non Hodgkin Lymphoma, Theratoma. 
 
The recovery day of haematic crasis after transplantation, the number of 
transfusions received from patients, the disease-free survival (DFS) and the 
overall survival (OS) have been evaluated.   
The haematic crasis is the day after stem cells re-infusion in which value of 
leucocytes is major than 1000 and platelets major than 20000 for 2 consecutive 
days. The average value of haematic crasis achievement has been the day 11 
(maximum value=19 in patient 14; minimum value=8 in patient 10). Not clear 
differences between diseases have been observed. 
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About the number of transfusions received from patients the mean has been 2.23 
transfusions of red irradiate cells (max value=12 in patient 20; minimum value =0 
in patients 3,6,10,11,15,16,18,19,21,24,25). Again, not differences between 
pathologies have been observed. As to disease-free survival (DFS), 13/19 patients 
(57.7%) relapsed after transplantation and the time free from re-infusion  to the 
relapse diagnosis is 2.8 months (min value= 1month in patients 2, 8,14; max 
value=18 months in patient 6). After a mean follow-up of months 33.8, 14 are alive 
patients (6/14 are completely recovered and 8/14 relapsed) and 5 are death 
(Fig.18). Survival is under study with a minimum value of 3 days (patient 1) and a 
maximum value of 52 months (patient 3). 
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Fig 18: Clinical follow-up at 33.8 months after transplantation. D: death, R: relapse, CR: complete 
remission 
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Furthermore, it is important to report the appearance of hyperthyroidism in patient 
3 and hypogonadism in patient 21. Also, secondary neoplasms occurred in two 
patients and in particular prostatic cancer in patient 11 and melanoma in patient 7. 
The figure 19 shows the correlation between array-CGH results and clinical follow-
up. 
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Fig 19: Correlation between array-CGH results and clinical follow-up. D/R: death or relapse; CR: 
complete remission. No significant differences between the two groups were revealed. 
In particular, 
-Patient 2 (affected by HL with  deletion of  2p16.1 region) showed progression of 
disease one month after the autologous transplantation. Because of the young 
age, the patient has been submitted to bone marrow allogenic transplantation after 
4 months from CD34+ cells re-infusion and he expired due to pulmonary infection.  
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Patient 3 (MM with duplication of chr11 between q12.2 and q13.4 bands in 12.38% 
of cells and including CCND1 gene) relapsed after 7 months from transplantation. 
Cytogenetic analysis have been performed before and after transplantation. 
Results were interesting, since before the transplantation the rearrangement of 
IgH gene was present in 3.3% of nuclei and a deletion of chromosome 6 (at 
q23q25 level); analysis performed after the transplantation revealed the deletion of 
chromosome 6 (but in a different region: q23qter) and later the reappearance and 
the amplification of CCND1. 
Last cytogenetic control revealed a deletion of chr 13. The patient is followed in 
Day Hospital Oncology and his disease is in progression. 
- Patients 8, 9, 10, 27 and 30 showed imbalances of chromosome 14 where IGH 
gene is present.  
Patient 27 and 30 have not accomplished CD34+ re-infusion therefore the follow-
up is performed only for patients 8, 9 and 10 (affected by HL). 
Patients 9 and 10 are completely in remission at 34 and 38 months from 
transplantation. 
Patient 8 relapsed. Particularly, he had one month of disease free time from and 
died one year after transplantation.  
- Patient 1 showed a number of imbalances higher than others and had a bad 
progression: he died 3 days after CD34+ cells re-infusion. 
-In patients 4, 5, 6, 7, 11, 12, 16, 28, 29 and 31 no imbalances have been found by 
a-CGH.  
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Because of the disease progression, patients 28, 29 and 31 have not been re-
infused and therefore excluded from follow-up analysis. In the 7 analyzed patients, 
the mean follow-up obtained has been 40 months (min value: 31 months in patient 
6; max value: 49 months in patient 12). 
Patients 7 and 12 died at 10 and 5 months from transplantation: patient 7 because 
affected by a secondary neoplasm (melanoma) and patient 12 because of the 
disease progression.  
Patient 4 relapsed at two months from re-infusion and he is in treatment at the  
Oncology Department.  
At patient 11 diagnosis of prostatic cancer has been performed after 24 months 
from re-infusion. 
Patient 6 relapsed at 31 months from transplantation and he is in treatment at the 
Oncology Department. 
Patients 5 and 16 are in completely remission at 34 and 22 months from 
transplantation. 
-For patients 13, 15, 18, 21, 35 and 36 the material was not good for a-CGH 
analysis. Patients 35 and 36 are in complete remission. 
On the other hand, patient 13 was in remission but 18 months after transplantation 
showed nodules at thyroid level. 
Patients 15, 18 and 21 relapsed. 
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DISCUSSION 
 
 
The role of hematopoietic stem cell transplantation (HSCT) in NHL, HL and MM is 
well established (Calderón-Cabrera C et al, 2013), but a complete evaluation of its 
relevance in the clinical story of the disease and in long-term course is still under 
debate. 
Indeed there is not enough evidence regarding whether transplantation is the best 
therapeutic approach in NHL and HL. Moreover, published data on long-term 
follow-up of high-risk lymphoma patients treated with HSCT are poor. 
The aim of this study was to evaluate the chromosome imbalances of stem cells 
collected for HSCT compared with clinic follow-up of lymphoma and myeloma 
patients who underwent to auto transplantation. 
Copious regions of imbalances have been found, also at a low clonality. 
These regions have been analyzed and compared to sequences present in  
http://projects.tcag.ca/variation/ site that reports all variations not directly linked 
with pathologies. In some of our patients altered regions were unique and not 
already known as CNPs. 
Among chromosome imbalances detected, some indicate patients scientifically 
interesting as to proportion of the anomalous clone and  gene content. 
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Patient (2) reveals in 14.5% of cells a deletion of chromosome 2 in p16.1 region 
where the REL oncogene is located (Curry et al, 2009); (Gilmore, 2011): as a 
consequence it was partially deleted. Alterations of REL oncogene are associated 
with numerous neoplasms among which Hodgkin lymphoma (Enciso-Mora et al, 
2010). The clinic follow up of the patient showed a relapse after one month from 
the transplantation and an overall survival of 4 months. In particular, cause of 
death was septic shock during the aplastic phase after the transplantation. 
Patient (3) shows in 12.38% of cells a duplication of chromosome 11 between 
q12.2 and q13.4 bands where CCND1 is located. In particular according to FISH 
nuclei, CCND1 was amplified in 3% of nuclei before the transplantation and in 
86% of nuclei after the transplantation. This patient showed also a deletion of 
chromosome 13 appeared at 2 years from transplantation. Clinically he relapsed 7 
months from transplantation and actually, still alive, he is still followed at the 
Oncology Department. 
Analysis of these results and clinic outcome of patients suggest that 
haematopoietic stem cells re-infusion can be a possible risk factor when the 
chromosome alteration compromises significant genes. 
These two cases indicate that the techniques used in this study could found a 
clinical application for a more accurate investigation of patients, and for their 
prognostic evaluation. 
Patients 8, 9, 10, 27 and 30 showed altered portion of chromosome 14 in q32.31-
q32.33 region where IgH gene is present and often rearranged in lymphomas and 
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myelomas. This region is also characterized by numerous benign CNVs so it is 
possible that array-CGH results are due to them. Translocations involving the IgH 
gene are frequent in lymphoma and, although cytogenetic information is lacking in 
these specific patients, we might speculate of imbalances associated with these 
translocations. 
Clinically, patient 8 relapsed, patients 9 and 10 are in complete remission at 34 
and 38 months from transplantation. 
Patients (1), (8) and (9) affected with MM and HL were significantly different from 
all the other patients taken into account, at a-CGH level. As depicted in results 
they showed a considerable number of imbalances, very far from other patients. 
Particularly patient (1) revealed 525 imbalances, patient (9) 128 and patient (8) 
103. In the first two cases the clinic course has been notably negative. Indeed, 
patient (1) expired after 3 days and patient (8) after 12 months from stem cells re 
infusion. Patient (9) is in complete remission at 34 months from transplantation. It 
is possible to hypothesize that the alterations revealed from array-CGH could be 
due to chemotherapy treatment at which patients were exposed before of stem 
cells mobilization, but one should remake that the same would apply also to all 
other patients. The phenomenon called chromotripsis was mentioned in 
Introduction and could be at the basis of the karyotypic disaster of these patients. 
In patients 4, 5, 6, 7, 11, 12, 16, 28, 29 and 31 no imbalances were found through 
a-CGH, although a deletion of chromosome 6 long arms was detected by 
cytogenetic studies in patients 6 and 11. 
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Because of the disease progression, patients 28, 29 and 31 have not been re-
infused. Patients 5 and 16 are in completely remission at 34 and 22 months from 
transplantation. Patients 4 and 6 relapsed at 2 and 31 months from re-infusion.  
To patients 7 and 11 have been diagnosed a secondary neoplasm after 1 month 
for patient 7 and 24 months for patient 11. Patients 7 died for melanoma at 10 
months after transplantation. Patient 12 relapsed 2 months from the re-infusion 
and died at 5 months after transplantation. 
At 36 months, the correlation between array-CGH results and clinical follow-up 
shows not significant differences between patients with and without imbalances.  
Also, it is important to highlight patient treatment consequences. Indeed, a cyto-
reducing treatment precedes the therapy for auto transplantation with the goal to 
eliminate cancer cells. Furthermore, in HSCT suitable MM patients, the treatment 
is performed in first line, while in HL and NHL patients this treatment is performed 
in second line or in case of high risk disease. This imply that submitted patients to 
transplantation obtained one or more lines of chemotherapy which could modify 
cytogenetic evidences.  
One of future steps of this study would be the correlation between array CGH and 
cytogenetic data during different phases of disease with the aim to monitor a 
cytogenetic profile. Indeed, cytogenetic data work as prognostic and therapeutic 
factors. For example, deletion of chromosome 13 in MM patients is a known 
negative prognostic factor which refers to more aggressive treatment. Therefore, 
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this kind of monitoring which implies a constant cytogenetic follow up could define 
new clinic-prognostic correlations. 
Different experimental data (Scott and Reece, 2011); (Fenk et al., 2012) show 
higher risk of secondary neoplasm after HSCT and strong incidence of relapse in 
spite of ASCT; therefore the identification of alterations before the re infusion could 
allow the use of therapies to purify the apheretic pool. 
Again, new information about pathogenesis of different tumours (Chen et al, 2007) 
could derive from the study of cancer stem cells or more significantly of a clone 
provided of characteristics similar to stem cells (auto-maintenance and migration 
ability). In this case would be important to extend the clinical observation. 
Finally, indications of global survival of the population considered may come from  
a continuous cytogenetic and clinic follow up during the time. 
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APPENDIX 
 
Chr Band  Start   Stop  Alterations NOTE 
1 q23.3 158,942,992 160,014,817 DUP   
2 p16.3 - p16.2 50,128,056 53,563,488 DEL   
3 p25.3 9,591,419 10,910,067 DUP   
6 p21.33 - p21.32 31,598,502 32,288,214 DUP   
7 p22.3 - p22.2 258,093 3,294,878 DUP TELOMERE 
7 p15.2 27,106,218 27,204,537 DEL   
7 p15.2 27,134,367 27,147,980 DEL   
7 p15.2 27,155,098 27,171,318 DEL   
7 q11.23 72,645,248 76,051,630 DUP   
7 q11.23 73,071,461 76,625,428 DUP   
8 p23.2 2,528,363 5,194,375 DEL   
11 q23.3 117,685,775 118,763,618 DUP   
14 q32.12 90,778,825 90,806,377 DEL IGH 
14 q32.12 92,445,797 92,477,585 DEL IGH 
14 q32.2 - q32.33 98,692,745 105,082,960 DEL IGH 
14 q32.2 98,704,114 98,713,479 DEL IGH 
14 q32.2 99,343,673 99,680,217 DUP IGH 
14 q32.2 99,819,676 99,845,672 DEL IGH 
15 q24.1 - q24.2 71,780,987 73,907,191 DUP   
16 p13.3 258,680 3,081,764 DUP TELOMERE 
16 q13 54,859,698 56,328,891 DUP   
16 q22.1 67,174,585 67,269,761 DEL CDH3 
19 p13.2 11,540,969 11,570,621 DEL ZNF GENE 
X p22.33 - p22.31 3,607,739 8,491,312 DEL   
X q28 152,369,803 153,127,227 DUP   
X q28 153,211,406 153,829,419 DUP   
 
 
 
 
 
Table A1:Found alterations in patient 1 (MM) 
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Chr Band  Start   Stop  Alterations NOTE 
1 p36.33 554.068 1.599.256 DUP TELOMERE 
1 p36.33 - p36.32 554.068 3.656.166 DUP TELOMERE 
11 p15.5 182.172 1.941.855 DEL AS LYMPHOMA 
11 p15.5 - p15.4 182.172 3.855.648 DUP AS LYMPHOMA 
11 p15.5 - p15.4 223.302 3.270.642 DUP AS LYMPHOMA 
Table A2: Common alterations found in patients 3 and 6 (MM) 
 
 
Chr Band  Start   Stop  Alterations NOTE 
1 q23.1 157,001,010 157,039,328 DEL   
2 q37.3 239,866,612 242,717,216 DUP   
4 q12 - q13.3 58,433,263 71,282,874 DEL   
4 q31.23 150,289,815 150,392,906 DEL   
6 p21.33 - p21.32 31,611,011 32,268,203 DUP   
6 p21.1 42,167,736 43,716,620 DUP   
7 q11.23 73,153,734 75,830,106 DUP   
10 p12.1 27,862,637 27,952,464 DEL   
10 p12.1 27,914,822 27,974,732 DEL   
10 q11.22 - q11.23 49,060,955 50,207,066 DUP   
10 q26.2 - q26.3 128,755,351 135,286,223 DUP   
10 q26.3 133,111,146 135,356,871 DUP   
14 q21.1 - q21.3 38,784,737 43,884,216 DEL   
16 p13.3 390,384 3,081,764 DUP TELOMERE 
17 p13.3 3,325,950 3,400,342 DEL   
20 p13 3,133,213 4,087,402 DUP   
X p11.23 47,393,800 47,406,832 DEL   
Table A3: Found alterations in patient 2 (HD) 
 
Chr Band  Start   Stop  Alterations NOTE 
17 q21.2 - q21.32 37,114,755 42,396,127 54.57% DUP 
17 q21.2 - q21.31 37,134,161 41,645,179 46.82% DUP 
17 q21.2 - q21.31 37,146,898 40,794,930 34.24% DUP 
Table A4: Common found alterations in patients 5, 7, 8, 9, 10,12, 27, 28, 30 and 31 (HD and NHL)
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